脑脊液储存量对自动化平台上阿尔茨海默病生物标志物分析的影响。
Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform.
机构信息
Université de Montpellier, CHU de Montpellier, Laboratoire de Biochimie-Protéomique clinique, INSERM U1183, Montpellier, France.; Sant Pau Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sant Pau Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Spain.
出版信息
Clin Chim Acta. 2019 Mar;490:98-101. doi: 10.1016/j.cca.2018.12.021. Epub 2018 Dec 20.
OBJECTIVES
To assess the potential influence of the ratio between the storage tube surface area and the volume of cerebrospinal fluid (CSF) (surface/volume) on the quantifications of four Alzheimer's disease (AD) biomarkers on the Lumipulse G600II automated platform.
METHODS
CSF samples of 10 consecutive patients were stored in 2 ml polypropylene tubes containing four different CSF volumes: 1.5 ml, 1 ml, 0.5 ml and 0.25 ml. Concentration of CSF Aβ1-42, Aβ1-40, t-Tau and p-Tau were measured in all aliquots using the LUMIPULSE G600II automated platform from Fujirebio.
RESULTS
Levels of CSF Aβ1-42 and Aβ1-40 were lower in samples stored with lower volumes (higher surface/volume ratios). This decrease was partly compensated by using the ratio Aβ1-42/Aβ1-40. Quantification of t-Tau and p-Tau were not influenced by this pre-analytical condition.
CONCLUSION
The surface/volume ratio can potentially influence the results of amyloid AD biomarkers. It appears essential to take into account the surface/volume ratio of the storage tubes when quantifying CSF biomarkers in clinical routine.
目的
评估脑脊液（CSF）存储管表面积与体积之比（表面积/体积）对 Lumipulse G600II 自动化平台上四种阿尔茨海默病（AD）生物标志物定量的潜在影响。
方法
将 10 例连续患者的 CSF 样本储存在含有 4 种不同 CSF 体积的 2ml 聚丙烯管中：1.5ml、1ml、0.5ml 和 0.25ml。使用 Fujirebio 的 LUMIPULSE G600II 自动化平台测量所有等分试样中 CSF Aβ1-42、Aβ1-40、t-Tau 和 p-Tau 的浓度。
结果
在体积较小（表面积/体积比较高）的样本中，CSF Aβ1-42 和 Aβ1-40 的水平较低。通过使用 Aβ1-42/Aβ1-40 比值，部分补偿了这种降低。t-Tau 和 p-Tau 的定量不受这种分析前条件的影响。
结论
表面积/体积比可能会影响淀粉样 AD 生物标志物的结果。在临床常规中定量 CSF 生物标志物时，似乎必须考虑存储管的表面积/体积比。
Zotero 插件